What do you know about After Biogen's big Alzheimer's drug data reveal, observers remain divided?
The data showed that drug significantly reduced the spread of a sticky plaque called amyloid beta that builds up in Alzheimer’s disease patients’ brain. The role that amyloid plays in Alzheimer's disease continues to be debated, and multiple drugs targeting the plaque have failed.
The point of contention for many assessing Biogen’s chances of an FDA approval is whether the drug led to strong enough improvements in cognition, memory and other impacts of the disease.
#bio
pain scale (1-10): 6
